Kornimate/medical-research-clean huggingface dataset:
a study to look at the health outcomes of patients with covid-19 and influenza

Conditions: COVID-19; Coronavirus Disease 2019; Influenza

Summary: the main purpose of this study is to understand: * the symptoms of covid-19 or influenza- health-related outcomes of people with covid-19 or influenza (influenza only included in updated study analyses) * the potential effects of covid-19 vaccines in people with covid-19 this study will enroll participants who are: * 18 years or older * reported to have symptoms with tests that have confirmed illness. the tests can be taken at any of cvs pharmacy covid-19 or influenza test sites. the study will collect vaccine history information from participants who are ready to take part in the study. participant will be emailed a form with questions about their health related to covid-19 or influenza during multiple follow-ups over a 6-month period.

this is a prospective non-interventional longitudinal cohort survey study. repeated measures on pros including: symptoms (prevalence, frequency, duration, and severity), eq-5d-5l, and wpai over 6 months will be collected and evaluated. covid-19 cohort: participants 18 years or older with test-confirmed covid-19 illness and at least one patient-reported symptom. influenza cohort: participants 18 years or older with test-confirmed influenza illness and at least one patient-reported symptom. all study objectives and outcomes will be assessed separately for the two study cohorts. influenza cohort is only included in updated study analyses.

Eligibility criteria:
inclusion criteria: * age 18 or older * self-reported at least one symptom in the cvs health pre-test screening questionnaire * positive result reported from diagnostic test for covid-19 (or influenza in updated analysis) * evidence of a signed and dated informed consent through electronic consent process indicating that the participant has been informed of all pertinent aspects of the study * able to complete the questionnaires by themselves in english or spanish exclusion criteria: - no symptoms reported in the study screening questionnaire

Keywords: patient-reported outcomes humanistic burden quality of life disease symptoms assessment covid-19 sars-cov-2 severe acute respiratory syndrome coronavirus 2 infection acute respiratory infection influenza human influenza
cardiovascular effects of evoo in healthy reproductive-aged women

Conditions: Hypertension; Vascular Stiffness

Summary: this study aims to compare changes in cardiovascular function and markers of inflammation and metabolic dysfunction in women randomized to treatment with extra virgin olive oil (evoo) versus those randomized to treatment with a control oil low in oleic acid and phenols for 8 weeks.

participants will be randomized to receive 45 ml (40 g) of extra virgin olive oil (evoo) daily for 8 weeks or an identical dose of a control sunflower seed oil low in oleic acid and phenol content. evoo high in oleic acid and phenolic content will be identified and shipped from italy and stored protected from heat and light in the bionutrition core at the clinical research center at the university of vermont medical center. women will undergo a detailed cardiovascular assessment at baseline and following treatment, including assessment of blood pressure, pulse-wave velocity, calculation of arterial distensibility and beta stiffness, flow-mediated vasodilation, cardiac output, response to volume challenge and dual-energy x-ray absorptiometry (dexa). lipid profiles and markers of inflammation, oxidative stress and metabolic dysfunction will also be assessed at both study visits. investigators hypothesize that treatment with high oleic acid and phenolic evoo will be associated with decreased blood pressure, improved vascular compliance and blood vessel function, and with improvement in lipid profile, inflammation and markers of metabolic dysfunction.

Eligibility criteria:
inclusion criteria: * women are eligible to participate if they are between the ages of 18 and 40, in good health, with regular menstrual cycles and no prior pregnancies. exclusion criteria: * routinely take medications or supplements known to affect blood pressure, heart or blood vessel function, or those with anti-inflammatory or antioxidant properties * smoking * pregnancy * other conditions that would impair adherence, such as allergy to olive oil or sunflower oil or difficulty swallowing
prospective data collection of patients undergoing gynecologic surgery

Conditions: Disease (or Disorder); Gynecological

Summary: the aim of this prospective study is to collect data on patients undergoing gynecologic surgery at kangbuk samsung hospital.

the aim of this prospective study is to collect data on patients undergoing gynecologic surgery at kangbuk samsung hospital. if patients agree to participate in this clinical trial, patient's data (such as age, body mass index, preoperative findings, laboratory findings, radiologic findings, operative findings, pathologic findings, postoperative findings) will be collected in a research database. the research database will be updated, every 6 month, to include data on patient's disease outcome and follow-up care. although most data will be collected form the medical record, patient may agin be contacted so that researchers can collection some data if it is not in the medical record.

Eligibility criteria:
inclusion criteria: * all patients undergoing gynecologic surgery at kangbuk samsung hospital since march, 2015 exclusion criteria: * none
hyperuricemia on hypertension and metabolic syndrome

Conditions: Systolic and Diastolic Blood Pressure Levels; Uric Acid Levels; Metabolic Syndrome Parameters; Hepatic Enzymes

Summary: the purpose of this study is to evaluate the influence of hyperuricemia treatment compared with placebo on participants with high risk of hypertension and metabolic syndrome.

elevated consumption of high fructose corn syrup has lead to an increase of 30% of fructose intake since the last 20 years. important data supporting this fact can be reflected on incidence and prevalence of metabolic syndrome and hyperuricemia. a peculiar effect of fructose intake demonstrated in animal models is the development of elevated uric acid levels; also some studies have found a clear association between hyperuricemia as an important risk factor for hypertension, diabetes mellitus, chronic kidney disease and metabolic syndrome. taking into account the existing evidence, our clinical research team presents this protocol as a way to evaluate the effect of uric acid treatment and its relation with fructose consumption, metabolic syndrome parameters, hyperuricemia and risk of hypertension. confirming evidence with clinical basis may be the initial strategy to create primary prevention programs to control this health problems affecting mexican population.

Eligibility criteria:
inclusion criteria: * adults with blood pressure from 120/80 mmhg and less than 140/90 mmhg * no pharmacological treatment for blood pressure control exclusion criteria: * hypertension (more than 140/90mmhg) * diabetes mellitus type 1 or 2 * chronic kidney disease (mdrd less than 60) * hepatic disease * malignancy * pregnancy * patient receiving any medication

Keywords: hypertension hyperuricemia metabolic syndrome
protocol for the quantitation of pain in the diagnosis of polymyalgia rheumatica

Conditions: Polymyalgia Rheumatica; Rheumatoid Arthritis; Rheumatic Disease

Summary: the aim of this study is to evaluate a simple and rapid method in order to better define and treat polymyalgia rheumatica by measuring levels of muscle achiness and pain with a blood pressure cuff.

this study is being conducted to evaluate a method for the quantifying of the proximal tenderness in patients with presumed diagnosis of polymyalgia rheumatica(pmr)using the measurements of pain thresholds(in both upper and lower arms) by the use of a standard blood pressure cuff. at the present time the diagnosis of pmr is based upon four classic criteria, history of sudden onset symmetric painful proximal myopathy, physical demonstrating proximal tenderness without loss of motion passively, laboratory evidence of significant inflammation: esr\>50 and treatment with a rapidly beneficial response to low dose prednisone. while the history, laboratory findings, and the response to prednisone are easily documented, the complaint of tenderness and the physical response to that tenderness is difficult to define and quantitate. by better quantifying the tenderness and the physical response to that tenderness will, it is hoped, lead to more rapid diagnosis as well as improved approach to treatment. three groups of patients will be studied. each patient, after written informed consent and procedure statement, will have pain threshold measurements taken and recorded by standard blood pressure cuff 4 times: one each on the lower and upper arms. the blood pressure cuff will be inflated to the level of maximum pain, then deflated, recording the maximum pain level. absolute numbers will be used for each measurement. blood pressure will not be recorded. this study is an attempt to add definition to the diagnosis of polymyalgia rheumatica with a both simple and rapid office exam.

Eligibility criteria:
inclusion criteria: * patients signing informed consent exclusion criteria: * patients less than 50 years old

Keywords: polymyalgia rheumatica rheumatoid arthritis rheumatic disease pmr
graded exposure therapy in chronic pelvic pain

Conditions: Chronic Pelvic Pain

Summary: chronic pelvic pain (cpp) is considered as nonmalignant recurrent or continuous pain related to the structures of the pelvis. the objective of this study was to evaluate the effects of graded exposure therapy in women with chronic pelvic pain.

chronic pelvic pain (cpp) is considered as nonmalignant recurrent or continuous pain related to the structures of the pelvis. this condition lasts at least 6 months, and many times is associated with negative cognitive, emotional, sexual and behavioral consequences.in addition to the high economic cost, cpp is also costly in emotional and psychological suffering. this clinical trial aims to evaluate the effects of a program based on graded exposure therapy in women with chronic pelvic pain.

Eligibility criteria:
inclusion criteria: * diagnosis of chronic pelvic pain * moderate fear of movement exclusion criteria: * other clinical diagnosis. * men * other pathology such as neurological disease. * cognitive impairment.

Keywords: women chronic pelvic pain fear avoidance
e-nose and inflammatory asthma phenotypes

Conditions: Persistent Asthma

Summary: patients with persistent asthma have different inflammatory phenotypes. the electronic nose is a new technology capable of distinguishing volatile organic compound breath-prints in exhaled breath among different pulmonary diseases. question of the study. is the electronic nose breath-print analysis able to discriminate among different inflammatory asthma phenotypes?

materials/patients and methods. fifty-two consecutively enrolled patients with persistent asthma were included in a cross-sectional proof of concept study. inflammatory asthma phenotypes were recognized by inflammatory cell counts in induced sputum. breath-prints were analyzed by discriminant analysis on principal component reduction, resulting in cross-validated accuracy values. receiver operating characteristics (roc) was calculated. legal and ethical aspects the study was conducted in accordance with the declaration of helsinki principles (18th word medical assembly, 1964) and was approved by the clinical research ethics committee (approval number: iibsp/10/122/1161) of our institution. the participants provided their written informed consent to participate in this study and personal identification data were anonymized.

Eligibility criteria:
inclusion criteria: adults with persistent asthma, defined as per the global initiative for asthma management (gina) criteria, and specifically with positive bronchodilator test, or a daily peak expiratory flow (pef) variability greater than 20%, or a positive methacholine challenge test documented in case history. subjects were consecutively enrolled from the outpatient visits of a specialized asthma unit located in a tertiary university hospital. exclusion criteria: subjects were excluded if they had a respiratory tract infection or asthma exacerbation within 30 days prior to inclusion or were receiving oral steroids or immunosuppressive treatments.

Keywords: asthma; inflammation; electronic nose
peezy midstream urine device compared to catheterized urine sample

Conditions: Lower Urinary Tract Symptoms; Lower Urinary Tract Infection

Summary: urine culture and microscopic urinalysis will be compared between 2 collection methods: peezy midstream urine collection, and urethral catheter collection.

female patients presenting to the baylor scott \& white health (temple, tx) urology clinic for complaints of lower urinary tract symptoms will be included. they will be approached by a clinical research coordinator and given more information. if they meet eligibility by screening, consents will be completed. patients will proceed with their regular clinic visit with their clinician. just prior to the physical exam, patients will use the peezy device to give a urine specimen in the privacy of the bathroom. the package with peezy includes the simple instructions for use. patients return to the clinic room and the physical exam proceeds. an in-and-out catheter is used to obtain a post-void residual as well as a control urine specimen. after the remainder of the patient routine exam is complete, they will fill out a brief questionnaire. the 2 specimens will then be delivered to the lab. the clinical research coordinator will store consents and questionnaires that include the subjects study identification number in individual opaque envelopes that will be kept in a locked drawer accessible to only the investigators.

Eligibility criteria:
inclusion criteria: * females presenting to the urology or urogynecology clinic for consultation or evaluation of lower urinary tract complaints. exclusion criteria: * known pregnancy * use of antimicrobial oral or vaginal therapy in the past 4 weeks * use of pyridium in the past 4 weeks

Keywords: urine specimen contamination
assess safety and efficacy of levetiracetam(lev;keppra)for seizure prevention

Conditions: Traumatic Brain Injury; Subarachnoid Hemorrhage

Summary: to show that the use of intravenous levetiracetam(lev;keppra)for seizure prevention in patients in the neuroscience intensive care unit will result in fewer side effects compared to the current standard of care anticonvulsant and will be at least as effective as the current standard of care in preventing clinical and sub-clinical seizure activity.

to show that the use of intravenous levetiracetam(lev;keppra)for seizure prophylaxis in the neuroscience intensive care unit will result in fewer adverse effects compared to the current standard of care anticonvulsant(phenytoin) and will be at least as effective as phenytoin in preventing clinical and sub-clinical seizure activity.

Eligibility criteria:
inclusion criteria: * subjects with traumatic brain injury * glasgow coma score (gcs) score 3-8(inclusive),or gcs motor score of 5 or less and abnormal admission ct scan showing intracranial pathology * hemodynamically stable with a systolic bp \>90 mm hg * at least one reactive pupil * a negative pregnancy test in females * age at least 18 years * signed informed consent and health insurance portability and accountability act (hipaa) authorization for research form or * subjects with subarachnoid hemorrhage (sah) * sah documented by ct scan * hunt-hess grade 3-5, inclusive * hemodynamically stable with a systolic bp\> 90 mm hg * at least one reactive pupil * a negative pregnancy test in females * age of at least 18 years * signed informed consent and hipaa authorization for research form exclusion criteria for enrollment * no venous access * spinal cord injury * history of or ct confirmation of previous brain injury such as brain tumor, cerebral infarct, or spontaneous intracerebral hemorrhage * hemodynamically unstable * suspected anoxic events * other peripheral trauma likely to result in liver failure * positive pregnancy test in females * age less than 18 years of age * known hypersensitivity to any anticonvulsant * an injury that, in the opinion of the principal investigator, has a high likelihood of death within the first 72 hours. * any treatment, condition, or injury that contraindicates treatment with lev (levetiracetam) or phenytoin (pht). * inability to obtain signed informed consent or hipaa authorization for research.

Keywords: seizures traumatic brain injury subarachnoid hemorrhage
the effect of probiotics on gingivitis

Conditions: Gingivitis; Chronic

Summary: the aim of the study is to assess the effect of oral probiotics containing streptococcus salivarius m18 on gingivitis and oral hygiene in young adults.

this will be a double-blind, randomized, placebo-controlled two-arm parallel-group study of the effect of oral probiotics containing streptococcus salivarius m18 on gingivitis and oral hygiene. the groups will include young adults with gingivitis diagnosed clinically. to assess the effect of oral probiotics, the following parameters will be used: gingival index, gi; gingival bleeding index, gbi and oral hygiene level (the turesky modification of the quigley-hein plaque index, tmqhpi).

Eligibility criteria:
inclusion criteria: * aged between 18-25 years * permanent bite; * presence of more than 20 teeth; * absence of systemic and chronic diseases; * the diagnosis of gingivitis stated clinically. exclusion criteria: * presence of mild, moderate or severe chronic periodontitis; * refusal to sign informed consent; * taking supplements and medication containing probiotics or prebiotics 1 months before the study; * taking antibiotics (within 3 months before the study); * allergy to the components of the drugs used in the study; * presence of immunodeficiency, taking immunosuppressants. * use of other hygiene products, immunostimulants and antibacterials, probiotics, prebiotics during the study; * refusal to take a given medication; * failure to attend check-ups.
invasive vs. conservative management in cancer patients with non-st elevation mi (can-nstemi)"

Conditions: Myocardial Infarction

Summary: this retrospective study investigates the impact of invasive versus conservative management strategies in cancer patients presenting with non-st elevation myocardial infarction (non-st mi). patients aged 18 and older, who were treated for non-st mi in a hospital setting and had a confirmed cancer diagnosis, are included. the primary outcome is hospital mortality, assessed using grace scores to evaluate mortality risk. patients are grouped based on their received interventions-either invasive (including coronary angiography and revascularization) or pharmacological treatment. risk factors contributing to mortality, such as cancer type, metastasis presence, comorbidities, and laboratory findings, will also be analyzed to better understand the interplay of oncologic and cardiovascular conditions in this population.


Eligibility criteria:
inclusion criteria: * age: patients aged 18 years and older. * diagnosis: patients with a confirmed cancer diagnosis. * acute condition: patients diagnosed with non-st elevation myocardial infarction (non-st mi). * treatment: patients who received either invasive treatment (including coronary angiography and revascularization) or conservative (pharmacological) treatment for non-st mi. * consent: patients who have provided informed consent or are part of a retrospective study where consent is waived. exclusion criteria: * age: patients younger than 18 years. * non-cancer diagnoses: patients without a cancer diagnosis. * st-elevation myocardial infarction: patients with st elevation myocardial infarction (stemi) instead of non-st elevation myocardial infarction (nstemi). * pre-existing severe comorbidities: patients with severe or terminal comorbidities (e.g., end-stage liver disease, end-stage renal disease, or severe cognitive impairment) that would confound the outcomes. * incomplete medical records: patients with missing data on relevant clinical variables (e.g., grace score, treatment received, or mortality data). * pregnancy: pregnant patients, as their conditions may complicate the interpretation of results. * inability to provide informed consent: patients unable to provide informed consent (if applicable).

Keywords: non-st elevated myocardial infarction malignancy mortality
a companion study for studies thal-mm-003, cc-5013-mm-009, and cc-5013-mm-010 for subjects with multiple myeloma

Conditions: Multiple Myeloma

Summary: the study evaluated the safety of lenalidomide monotherapy in participants with advanced multiple myeloma who had discontinued treatment with combination thalidomide plus high-dose dexamethasone or high-dose dexamethasone alone in studies thal-mm-003, cc-5013-mm-009 and cc-5013-mm-010 due to the development of documented disease progression or the inability to tolerate the lowest dosing regimen per previous protocol of thalidomide and/or high-dose dexamethasone without grade 3 or 4 toxicity.


Eligibility criteria:
inclusion criteria: * understand and voluntarily sign an informed consent form. * age ≥ 18 years at time of signing the informed consent form. * able to adhere to the study visit schedule and other protocol requirements * participants with multiple myeloma and were enrolled in either thal-mm-003, cc-5013-mm-009, or cc-5013-mm-010 and discontinued study therapy with thalidomide and high-dose dexamethasone or high-dose dexamethasone alone due to: documented disease progression or inability to tolerate the lowest dosing regimen allowed on previous protocol without a grade 3 or 4 toxicity. * eastern cooperative oncology group (ecog) performance status score 0,1,2 * recovery from thalidomide or dexamethasone-related toxicity to ≤ grade 2 (nci ctc) * females of child-bearing potential (fcbp) must agree to using two methods of contraception exclusion criteria: * prior development of a ≥ grade 2 allergic reaction/hypersensitivity or prior development of a grade ≥ 3 rash or desquamation while taking thalidomide national cancer institute common toxicity criteria (nci ctc) * use of any standard/experimental anti-myeloma therapy within 28 days of randomization or use of any experimental non-drug therapy within 56 days of initiation of drug treatment * any serious medical condition, laboratory abnormality, or psychiatric illness that will prevent the participant from signing the informed consent form or that will place the participant at an unacceptable risk for toxicity if he/she participates in the study. * pregnant or lactating females. * prior therapy with cc-5013; prior history of malignancies, other than multiple myeloma (except basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast), unless subject has been free of disease for ≥ 5 years * more than 4 months has elapsed since the last dose of study drug was administered on study tal mm-003, cc-5013-mm-009, cc-5013-mm-010 * absolute neutrophil count (anc) \<1,000cells/mm\^3 (1.0 x 10\^9/l) * platelet count \<75,000/mm\^3 (30 x 10\^9/l) for those with \<50% if the bone marrow nucleated cells re plasma cells; platelet count \<30,000/mm\^3 (30 x 10\^9/l) for those with \<50% if the bone marrow nucleated cells re plasma cells * serum creatinine \>2.5mg/dl; serum sgot/ast or sgpt/alt x upper limits of normal (uln) * serum total bilirubin \>2.0mg/d/l

Keywords: multiple myeloma revlimid